SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
CVAS-an interesting california-based biotech company here
An SI Board Since September 1999
Posts SubjectMarks Bans Symbol
126 13 0 CVAS
Emcee:  kendall harmon Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
51Approvable??? Without explanation! What is wrong? Safety? Thursday August 16, 6Miljenko Zuanic-8/16/2001
50Drug firms await FDA ruling on Arixtra BY MARK COURT, HEALTH INDUSTRIES CORRESMiljenko Zuanic-8/14/2001
49Arteriosclerosis, Thrombosis, and Vascular Biology. 2001;21:1301.) © 2001 AMiljenko Zuanic-8/9/2001
48good entry on CVAS, I missed itkendall harmon-7/24/2001
47up over $1 so far.zx-7/24/2001
46bouncing back. wonder which big investor got out. great time to get some sharezx-7/24/2001
45This morning news: biz.yahoo.com <<The increased operating expenses in tMiljenko Zuanic-7/24/2001
44AstraZeneca's Novel Oral Anticoagulant Studied as Alternative to Warfarin Rekeokalani'nui-7/9/2001
43Can't confirm, but if true it is good news for Corvas c2 protein. AstraZeneMiljenko Zuanic-6/22/2001
42Sound like step forward. One speculative note: data from aCS trial (four doses)Miljenko Zuanic-6/6/2001
41Corvas Completes Phase IIa Angioplasty Trial With rNAPc2 Anticoagulant SAN DIEGOkeokalani'nui-6/6/2001
40<<Corvas International Inc. (CVAS - news) and Texas Biotechnology Corp. (TMiljenko Zuanic-5/29/2001
39Pru cut apparently not based on anything new at the company, or change in judgmekeokalani'nui-5/29/2001
38Today Pru cut its cvas rating from Strong buy to hold. I do not access to theirkeokalani'nui-5/29/2001
37Well, it was TROUBLED Jonus C.C., and Tupelo C.M., and Strong Capital M. who solMiljenko Zuanic-5/17/2001
36Significant interest among bios and pharmas for new anti-thrombotic agents. OraMiljenko Zuanic-5/1/2001
35Myridad. Preclinical anti-thrombotic. Myriad Genetics Drug Enters Preclinical keokalani'nui-5/1/2001
34Other side is doing well. Thursday April 26, 9:53 am Eastern Time Press ReleaseMiljenko Zuanic-4/26/2001
33Glycine Antagonist Fails to Improve Function in Ischemic Stroke Patients ------Miljenko Zuanic-4/6/2001
32Low-Dose Heparin Equal to Low-Molecular-weight Heparin For DVT Prophylaxis ----Miljenko Zuanic-4/3/2001
31<<Functional and neurological outcomes will be assessed in this new multi-Miljenko Zuanic-3/9/2001
30Wilder, IMO, there is no way that you can administrate (surgery) antitrombotic Miljenko Zuanic-3/3/2001
29Milkenko, do you know if the NEJ article published the bleeding rates by dose? keokalani'nui-3/2/2001
28High doses have side effects, lower doses didn't show any advantage. What Miljenko Zuanic-3/1/2001
27MZ, sorry to stalk you here. For those (like me) who didn't already know: keokalani'nui-2/26/2001
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News